Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the... see more

NDAQ:ACST - Post Discussion

Acasti Pharma Inc > Incorrect design trial
View:
Post by Francine01 on Jun 29, 2020 4:59pm

Incorrect design trial

More I think about this call, more I think they incorrectly design the trial and won't ever admit, Jan need to be replaced. 

Its impossible that they can't control a placebo arm. If its the case, other trials would have fail and no investor would invest in a R&D if they can't control the placebo arm. 

Basically, the trial was incorrectly design, patients should not have been put on a severe diet during randomization, because it reduce significantly the TG, this is not rocket science.

Also, how could patients would be >500 mg/dl between randomization and under <500 mg/dl at week 0 and still be accepted as part of the research, it was designed for a fail. 

Are only hope is that T2 has not the same effect.

Management should leave. 

The conclusion, is that drug work, but trial incorrectly managed by incompetents
Comment by Rosmorduc on Jun 29, 2020 5:18pm
Every word you are stating Francine - I agree with 100%. The BOD had the chance to flush Jan out last year but Haywood came to her rescue (don't know why?). We are stuck with her incompetence and evasiveness now...she just wasted 6 monhts of shareholder's valuable time leaving us in the dark. And it is incompetence because it doesn't take a doctor to know that severe diet reduces TG ...more  
Comment by EternalPonzi on Jun 29, 2020 6:29pm
Yep.  Good luck getting rid of them.  They have a nice Iittle racket going and will fight tooth and nail to maintain their positions until the money runs out.  They have gifted themselves some very lucrative monetary rewards and very little to show for it during the past 12 months.  When the time comes to raise more funds, which is inevitable, hopefully they only raise what ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities